BRIEF-Amarin reduces it cardiovascular outcomes study of Vascepa
September 12, 2016 at 05:59 AM EDT
* It cardiovascular outcomes study of Vascepa to continue as planned at recommendation of independent data monitoring committee
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.